Related Experiment Video

Updated: May 29, 2026

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies

Published on: July 28, 2020

Therapeutic pipeline for soft-tissue sarcoma

Philippe A Cassier1, Sana Intidhar Labidi-Galy, Pierre Heudel

  • 1Département de Médecine, Centre Léon Bérard, 69008 Lyon, France. cassierp@hotmail.com

Expert Opinion on Pharmacotherapy
|September 15, 2011
PubMed
Abstract

Insights

Targeted agents show promise for specific soft-tissue sarcoma (STS) subtypes, advancing treatment beyond traditional chemotherapy. Further research is needed to fully understand the molecular biology of these diverse cancers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Soft-tissue sarcomas (STS) are a diverse group of connective tissue cancers.
  • Tumor heterogeneity has driven molecular classification and targeted therapy development.
  • Targeted agents have shown efficacy in specific STS molecular subgroups.

Purpose of the Study:

  • To review the rationale and clinical outcomes of subtype-directed targeted therapy in STS.
  • To discuss the development of targeted agents for advanced STS.
  • To highlight the limitations of current non-histotype-specific chemotherapies.

Main Methods:

  • Literature search of PubMed using keywords: 'sarcoma', 'angiogenesis', 'mTOR', 'targeted agents'.
  • Searched proceedings from American Society of Clinical Oncology and Connective Tissue Oncology Society meetings.
  • Focused on subtype-specific targeted agents for advanced STS, excluding non-histotype-specific chemotherapies.

Main Results:

  • Subtype-directed therapies represent a significant advancement in STS treatment.
  • Targeted agents have demonstrated activity in specific molecularly defined STS subgroups.
  • Clinical data on many targeted agents are primarily available for advanced disease.

Conclusions:

  • The development of subtype-specific agents marks progress in managing heterogeneous STS.
  • Significant research is still required to deepen the understanding of STS molecular heterogeneity.
  • Personalized medicine approaches are crucial for improving outcomes in soft-tissue sarcomas.

More Related Videos

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...